An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Announces Results from CAH Treatment Trials On December 11, Spruce Biosciences, Inc., announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Spruce is a late-stage...
Building Your Path and Enjoying Your Clinician/Educator Journey
Zeb Saeed, MD, a member of the steering committee for the Early-Career Special Interest Group (SIG), says that endocrinologists are trained to understand and translate complex processes, which makes them an educator at heart. Here, she gives some valuable key points to navigate the clinician/educator career journey. As endocrinologists, we are innate educators at heart. ...
Recipients of the Endocrine Society’s 2025 Edwin B. Astwood Award for Outstanding Research in Basic Science, David Mangelsdorf, PhD, and Steven Kliewer, PhD, have spent a lot of time in the lab with drunken mice. Find out how these besotted rodents may hold the secrets behind the evolution of how fibroblast growth factor 21 might...Early-Life Exposure to Toxic Chemicals May Cause Behavioral, Psychological Problems
Early life exposure to a class of endocrine-disrupting chemicals (EDCs) called polychlorinated biphenyls (PCBs) may lead to behavioral problems in rats, according to a new animal study published in the Journal of the Endocrine Society. Endocrine-disrupting chemicals (EDCs) are chemicals that mimic, block or interfere with hormones in the body’s endocrine system and contribute to endocrine...
Lorenzo Smith takes his passion for science all the way to Capitol Hill PhD candidate Lorenzo Smith recently experienced his first Hill Day with the Endocrine Society’s advocacy team and discusses what the lawmakers shared with him about the importance of scientific research, as well as the heartfelt reason he first became interested in a...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric...
The Endocrine Society’s 2025 recipient of the Gerald D. Aurbach Award for Outstanding Translational Research, V. Krishna Chatterjee, MD, tells Endocrine News why it’s so important for clinicians and basic scientists to work together to improve human health. In 2021, when our lives were still gripped by the deadly COVID-19 pandemic, V. Krishna Chatterjee, MD,...2024 Marked Year of Significant Accomplishments at the Society
It has been a remarkable year for the Endocrine Society! As the year draws to a close it’s timely to reflect on what we achieved over the past 12 months. Over this year we launched two new meetings, merged with an endocrine program directors’ association, entered partnerships to enhance our educational offerings, and created a...
